A Robert D Bailey bought $250K of Bausch + Lomb (BLCO)
Executed Mar 6, disclosed Mar 10, 4 days later.
Over the 21 trading sessions from the disclosed entry session (Mar 10), the stock returned -3.3% (delay-adjusted); from the execution session (Mar 6), -5.0%. Derived: entry at the session's open, exit at the close 20 sessions later.
A Robert D Bailey (EVP & Chief Legal Officer) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Bausch + Lomb Corporation (BLCO). Across 1 priced purchase filing, the average 21-session return was -5.0% from execution and -3.3% from disclosure (delay-adjusted; derived). The largest single filing was $250K of BLCO (14,600 sh × $17.15, as filed), executed Mar 6.
Healthcare · Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Ki…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→